THERAGEN ETEX CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,945 KRW | -0.63% |
|
-1.38% | -11.74% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 193B 143M 11.91B | Sales 2023 | 222B 164M 13.66B | Capitalization | 143B 106M 8.81B |
|---|---|---|---|---|---|
| Net income 2022 | 9.56B 7.08M 589M | Net income 2023 | 26.21B 19.4M 1.61B | EV / Sales 2022 | 0.78 x |
| Net Debt 2022 | 9.8B 7.25M 604M | Net Debt 2023 | 13.02B 9.63M 802M | EV / Sales 2023 | 0.7 x |
| P/E ratio 2022 |
14.8
x | P/E ratio 2023 |
5.46
x | Employees | 201 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.73% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.63% | ||
| 1 week | -1.38% | ||
| Current month | -0.88% | ||
| 1 month | +1.28% | ||
| 3 months | -5.17% | ||
| 6 months | -5.05% | ||
| Current year | -11.74% |
1 week
3 910.00
4 030.00
1 month
3 840.004 040.00
Current year
3 785.004 900.00
1 year
3 730.005 530.00
3 years
3 650.009 280.00
5 years
3 650.0014 550.00
10 years
3 650.0022 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Byeong-Hwan Ryu
CEO | Chief Executive Officer | 65 | - |
Jin-Up Go
CEO | Chief Executive Officer | 72 | 13/06/13 |
Tae-Soon Hwang
BRD | Director/Board Member | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin-Up Go
CEO | Chief Executive Officer | 72 | 13/06/13 |
Kun-Sik Choi
BRD | Director/Board Member | 79 | - |
Byeong-Hwan Ryu
CEO | Chief Executive Officer | 65 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 3,945 | -0.63% | 32,764 |
| 16/24/16 | 3,970 | +0.13% | 50,207 |
| 14/24/14 | 3,965 | 0.00% | 54,930 |
| 13/24/13 | 3,965 | -0.88% | 67,989 |
| 10/24/10 | 4,000 | -0.25% | 31,174 |
End-of-day quote Korea S.E., May 17, 2024
More quotes
THERAGEN ETEX CO.LTD. is a Korea-based company engaged in the industrial equipment business, healthcare and genome business and pharmaceutical business. The Company operates its business through three divisions: flat panel display (FPD) manufacturing equipment division, which provides loading and unloading systems, printed circuit board (PCB) bonding systems, battery washing lines and laser systems; healthcare and genome division engages in the provision of genome analysis services and others, and pharmaceutical division engages in the manufacture of digestive system remedies, antibiotics, remedies for fever, circulatory system remedies, respiration system remedies, treatment for chronic hepatitis, diabetes remedies, psychotropic agents, osteoporosis treatments and others.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.74% | 93.31M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- A066700 Stock
